This approach has led to the demonstration of the retinoprotective effects of PACAP in models of retinal hypoperfusion (Atlasz et al. 2007), traumatic optic nerve injury (Seki et al. 2008), kainate- and glutamate-induced excitotoxicity (Atlasz et al. 2009; Seki et al. 2006), UV light-induced lesion (Atlasz et al. 2011), lipopolysaccharide-induced inflammation (Vaczy et al. 2018), oxygen-induced retinopathy of prematurity (Kvarik et al. 2016), diabetic retinopathy (D’Amico et al. 2017; Szabadfi et al. 2016) and high intraocular pressure-induced retinopathy (Seki et al. 2011). Here, ADCYAP1 is linked to diabetic retinopathy.